The stock of Motif Bio PLC (LON:MTFB) is a huge mover today! The stock decreased 9.17% or GBX 2.75 on November 18, hitting GBX 27.25. About 7.78M shares traded hands or 3875.84% up from the average. Motif Bio PLC (LON:MTFB) has declined 25.93% since April 19, 2016 and is downtrending. It has underperformed by 30.36% the S&P500.
The move comes after 6 months negative chart setup for the GBX 24.22M company. It was reported on Nov, 18 by Barchart.com. We have GBX 23.44 PT which if reached, will make LON:MTFB worth GBX 3.39 million less.
Motif Bio PLC (LON:MTFB) Ratings Coverage
Out of 2 analysts covering Motif Bio Plc (LON:MTFB), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Motif Bio Plc has been the topic of 40 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Monday, March 14 by Northland Capital. As per Wednesday, October 14, the company rating was maintained by Beaufort Securities. Beaufort Securities maintained it with “Speculative Buy” rating and GBX 110 target price in Friday, August 28 report. The rating was maintained by Northland Capital on Tuesday, September 29 with “Buy”. The rating was maintained by Beaufort Securities with “Speculative Buy” on Tuesday, March 15. The stock has “Buy” rating given by Northland Capital on Wednesday, April 20. The stock of Motif Bio PLC (LON:MTFB) earned “Speculative Buy” rating by Beaufort Securities on Tuesday, January 26. The rating was maintained by Beaufort Securities with “Speculative Buy” on Thursday, March 3. The firm earned “Speculative Buy” rating on Friday, September 4 by Beaufort Securities. The stock has “Buy” rating given by Northland Capital on Wednesday, March 23.
More news for Motif Bio PLC (LON:MTFB) were recently published by: Reuters.com, which released: “BRIEF-Motif Bio Plc’s ADS opens at $5.52 in US market debut” on November 18, 2016. Uk.Finance.Yahoo.com‘s article titled: “Motif Bio Plc (MTFB.L)” and published on April 02, 2015 is yet another important article.
Motif Bio plc is a clinical-stage biopharmaceutical company. The company has a market cap of 24.22 million GBP. The Firm is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It currently has negative earnings. It operates in the development and commercialization of pharmaceutical formulations segment.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.